Edward Clouston MacPherson - 16 Apr 2026 Form 4 Insider Report for Telomir Pharmaceuticals, Inc. (TELO)

Reporting relationship: Director
Issuer ticker: TELO
Reported as of: 16 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jul 2026, 16:30:11 UTC
Prior SEC filing: 10 Dec 2024
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Ned MacPherson

Key filing fact

Edward Clouston MacPherson filed Form 4 for Telomir Pharmaceuticals, Inc. (TELO) on 27 Jul 2026.

Key facts

This page summarizes Edward Clouston MacPherson's Form 4 filing for Telomir Pharmaceuticals, Inc. (TELO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jul 2026, 16:30.

Change

Previous filing in this sequence was filed on 10 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002015989 Primary reporting owner

MacPherson Edward Clouston

Relationship: Director
Address: C/O TELOMIR PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, MIAMI
Signature: /s/ Ned MacPherson
Signature date: 27 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TELO transaction Derivative

Non-Qualified Stock Options (right to buy)

Award

Transaction value
Shares: +50,000
Change %
Price: $0.000000^*
Shares after: 50,000
Date: 16 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $1.34
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.

Footnote F2

The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.